Allegra Brand Revision Will Sell Romance, Emotion
This article was originally published in The Tan Sheet
Executive Summary
The OTC Allegra package branding when launched in March 2011 was limited by FDA until after the product lost market exclusivity, consultant Terri Goldstein says. Loss of market exclusivity opened the door to make Allegra branding “how we wished the package could have looked,” she says.
You may also be interested in...
Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.